Intraoperative dexamethasone intravitreal implant in high-risk uveitic cataract phacoemulsification

Session Details

Session Title: Cataract Surgery: Complications & Management

Session Date/Time: Tuesday 17/09/2019 | 14:00-16:00

Paper Time: 14:12

Venue: Free Paper Forum: Podium 1

First Author: : L.Santana García SPAIN

Co Author(s): :    M. Cordero-Coma   C. Plaza-Laguardia   J. Sanchez-Cañizal   P. Soler-Bartrina   E. Pastenes-Zhilin   M. Regal Rodriguez              

Abstract Details

Purpose:

To describe the outcome of intraoperative intravitreal dexamethasone (DXM) implant during cataract phacoemulsification in patients with high-risk uveitis.

Setting:

Retrospective non-comparative observational case series.

Methods:

Patients with high risk uveitis undergoing cataract phacoemulsification were included. We define “high risk uveitis” as: presence of macular edema (current or in the past) and/or one or more uveitis relapses in the last year. Data recorded from preoperative and 1-, 3-, 6- and 12 months postoperative visits included: visual acuity, IOP, treatments, clinical findings of inflammation, presence of uveitic macular edema, central macular thickness (CMT) and macular volume.

Results:

Twenty-seven eyes from 20 patients were included. There was a statistically significant improvement in VA logMAR at 1-,3- ,6-, and 12 months postoperatively when compared with that at baseline (P<0,001 for all comparisons). There was a statistically significant reduction in mean CMT 1 month after surgery (306,37±84,1µm) compared to baseline (347,87±141,2µm)(p<0,05). There were no major complications after DEX implantation.

Conclusions:

Preliminary results show that intravitreal dexamethasone implant might be an effective alternative to systemic steroids in high-risk uveitis patients for preventing uveitis relapses, trying to maximize the results in VA and CMT. No significant side effects related to this intervention were observed.

Financial Disclosure:

None